It is planned to produce 39 types of medicines in Israel, including biological preparations. An investment project aimed at launching the production of biological preparations and pharmaceutical materials will be implemented in Kazakhstan. At the cabinet meeting chaired by Prime Minister Oljas Baktanov, Faruch Razeev, CEO of "Abdi Ibrahim Global Pharm" LLP, reported on the plan. On January 24, 2026, an investment agreement with a total cost of 39 billion tenge was signed with the Ministry of Health. The project is implemented by the Kazakh-Turkish joint venture "Abdi Ibrahim Global Pharm" LLP, which has been operating in the pharmaceutical market of Kazakhstan since 2000. As part of the project, the localization of 39 types of medicines with international names without a patent is planned. The total number is 40 drugs and 82 positions in 13 therapeutic areas. Among them are currently 26 medical products and 13 biological products that are delivered to Kazakhstan from abroad. In addition to the production of finished drugs, the creation of pharmaceutical materials for biological preparations, the transfer of technologies and the development of scientific research activities are expected. The production will be launched in stages. It is planned to release the first drugs in 2027-2028. In 2029, 17 medical products will be put into production in new directions for domestic production, including nephrology, endocrinology, rheumatology and treatment of pulmonary hypertension. And in 2031, it is planned to release eight new products mainly in the fields of oncology, hematology, neurology and ophthalmology. A significant part of them today belongs to the category of expensive drugs purchased from abroad. Cooperation with the international pharmaceutical companies Pfizer and AstraZeneca was created as a separate direction of the project. In Kazakhstan, contracts were signed to organize the production of a vaccine against pneumococcal infection and a targeted drug for the treatment of leukemia.

It is planned to produce 39 types of medicines in Israel, including biological preparations. An investment project aimed at launching the production of biological preparations and pharmaceutical materials will be implemented in Kazakhstan. At the cabinet meeting chaired by Prime Minister Oljas Baktanov, Faruch Razeev, CEO of "Abdi Ibrahim Global Pharm" LLP, reported on the plan. On January 24, 2026, an investment agreement with a total cost of 39 billion tenge was signed with the Ministry of Health. The project is implemented by the Kazakh-Turkish joint venture "Abdi Ibrahim Global Pharm" LLP, which has been operating in the pharmaceutical market of Kazakhstan since 2000. As part of the project, the localization of 39 types of medicines with international names without a patent is planned. The total number is 40 drugs and 82 positions in 13 therapeutic areas. Among them are currently 26 medical products and 13 biological products that are delivered to Kazakhstan from abroad. In addition to the production of finished drugs, the creation of pharmaceutical materials for biological preparations, the transfer of technologies and the development of scientific research activities are expected. The production will be launched in stages. It is planned to release the first drugs in 2027-2028. In 2029, 17 medical products will be put into production in new directions for domestic production, including nephrology, endocrinology, rheumatology and treatment of pulmonary hypertension. And in 2031, it is planned to release eight new products mainly in the fields of oncology, hematology, neurology and ophthalmology. A significant part of them today belongs to the category of expensive drugs purchased from abroad. Cooperation with the international pharmaceutical companies Pfizer and AstraZeneca was created as a separate direction of the project. In Kazakhstan, contracts were signed to organize the production of a vaccine against pneumococcal infection and a targeted drug for the treatment of leukemia.